DEVELOPMENT OF REALTIME QUANTITATIVE PCR ASSAY FOR DETECTION AND MONITORING OF BCR ABL1 P190 TRANSCRIPT IN ACUTE LYMPHOBLASTIC LEUKEMIA

http://dx.doi.org/10.31703/gdddr.2022(VII-IV).05      10.31703/gdddr.2022(VII-IV).05      Published : Dec 4
Authored by : GulshanMunir , Gulrukh , HafsaTariq , ShaziaAmbreen , Hamed MahabatKhan , ShehlaRiaz

05 Pages : 39-47

References

  • Huang, Y. J., Kuo, M. C., Jaing, T. H., Liu, H. C., Yeh, T. C., & Chen, S. H. (2021). Comparison of two quantitative PCR–based assays for detection of minimal residual disease in B-precursor acute lymphoblastic leukaemia harbouring three major fusion transcripts. The Journal of Molecular Diagnostics. 23(10), 1373-9 https://doi.org/10.1016/j.jmoldx.2021.07.008
  • Martinez, R. J., Kang, Q., Nennig, D., Bailey, N. G., Brown, N. A., & Betz, B. L. (2022). One- Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. Archives of Pathology & Laboratory Medicine. 146(1), 92-100. https://doi.org/10.5858/arpa.2020-0454-OA
  • Beldinanzi, M., Della, S. I., Cardinali, D., Bellomarino, V., Elia, L., & Matarazzo, M. (2022). Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis . Blood. 140, 11866-7. https://doi.org/10.1182/blood-2022-163141
  • Ansuinelli, M., Della, S. I., Lauretti, A., Elia, L., Siravo, V., & Messina, M. (2021). Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. Hematological Oncology. 39(5), 680-6. https://doi.org/10.1002/hon.2913
  • Guan, Y., Zhang, M., Zhang, W., Wang, J., Shen, K., & Zhang, K. (2021). Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy. Frontiers in Oncology. 11, 646499. https://doi.org/10.3389/fonc.2021.646499
  • Saha, J., Gopinath, V., Nair, C. K., & Roshan, D. (2023). Identification of rare atypical BCR- ABL1 transcript: A case report. https://doi.org/10.4103/ijpm.ijpm_715_21
  • Saygin, C., Cannova, J., Stock, W., & Muffly, L. (2022). Measurable residual disease in acute lymphoblastic leukaemia: methods and clinical context in adult patients. Haematologica. 107(12), 2783-93. https://doi.org/10.3324/haematol.2022.280638
  • Tierens, A., Stockley, T. L., Campbell, C., Fulcher, J., Leber, B., & McCready, E. (2021). Consensus recommendations for MRD testing in adult B-cell acute lymphoblastic leukaemia in Ontario. Current Oncology. 28(2), 1376-87. https://doi.org/10.3390/curroncol28020131
  • Stella, S., Gottardi, E. M., Favout, V., Barragan, G. E., Errichiello, S., & Vitale, S. R. (2019). The q-lamp method represents a valid and rapid alternative for the detection of the bcr-abl1 rearrangement in Philadelphia-positive leukaemias . International Journal of Molecular Sciences. 20(24), 6106. https://doi.org/10.3390/ijms20246106
  • Fukutsuka, K., Kuramura, A., Nakagawa, M., Takahashi, R., Chagi, Y., & Nakagawa, M. (2022). Philadelphia chromosome-positive acute lymphoblastic leukaemia carrying the p230 μ-BCR-ABL1 fusion gene. Tenri Medical Bulletin, 25(1), 29-40. https://doi.org/10.12936/tenrikiyo.25-006
  • Chong, S. L., Asnawi, A. W. A., Leong, T. S., Tan, J. T., Law, K. B., & Hon, S.L. (2021). Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukaemia. Blood research. 56(3), 175-83. https://doi.org/10.5045/br.2021.2021045
  • Smith, B. M., Brewer, D., Druker, B. J., & Braun, T. P. (2021). Navigating challenges in monitoring chronic myeloid leukaemia with multiple BCR-ABL1 transcripts. Case Reports in Oncology. 14, 1707-11. https://doi.org/10.1159/000520400
  • Piedimonte, M., Ottone, T., Alfonso, V., Ferrari, A., Conte, E., & Divona, M. (2019). A rare BCR-ABL1 transcript in Philadelphia- positive acute myeloid leukaemia: case report and literature review. BMC cancer. 19, 1-6. https://doi.org/10.1186/s12885-019-5265-5
  • Chen, Y., Lu, Q. Y., Lu, J. Y., & Hong, X. L. (2022). Primary isolated central nervous system acute lymphoblastic leukaemia with BCR-ABL1 rearrangement: A case report. World Journal of Clinical Cases. 10(13), 4242. https://doi.org/10.12998/wjcc.v10.i13.4242
  • Pfeifer, H., Cazzaniga, G., Van der Velden, V., Cayuela, J., Schäfer, B., & Spinelli, O. (2019). Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukaemia. 33(8), 1910-22. https://doi.org/10.1038/s41375-019-0413-0
  • Podvin, B., Guermouche, H., Roynard, P., Goursaud, L., Berthon, C., & Ouafi, M. (2022). Subclonal acquisition of a BCR:: ABL1 fusion in chronic myelomonocytic leukaemia. Annals of Hematology, 101(9), 2093-5. https://doi.org/10.1007/s00277-022-04861-4
  • Zuna, J., Hovorkova, L., Krotka, J., Koehrmann, A., Bardini, M., & Winkowska, L. (2022). Minimal residual disease in BCR:: ABL1- positive acute lymphoblastic leukaemia: different significance in typical ALL and in CML-like disease. Leukaemia, 1-9. https://doi.org/10.1038/s41375-022-01668-0
  • Shires, K., & Rust, A. (2020). Novel multiplex RT-PCR assay to detect BCR/ABL mRNA variants. The Journal of Medical Laboratory Science and Technology of South Africa. 2(1), 29-35.
  • Correia, R. P., Bento, L. C., Sousa, F. A., Barroso, R. S., Campregher, P. V., & Bacal, N. S. (2021). How I investigate minimal residual disease in acute lymphoblastic leukaemia. International Journal of Laboratory Hematology. 43(3), 354-63. https://doi.org/10.1111/ijlh.13463
  • Short, N. J., Jabbour, E., Albitar, M., de Lima, M., Gore, L., & Jorgensen, J. (2019). Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukaemia: a consensus of North American experts. American journal of haematology, 94(2), 257- 65. https://doi.org/10.1002/ajh.25338
  • Della Starza, I., De Novi, L. A., Elia, L, Bellomarino, V., Beldinanzi, M., & Soscia, R, (2023). Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers. 15(2), 374. https://doi.org/10.3390/cancers15020374

References

  • Huang, Y. J., Kuo, M. C., Jaing, T. H., Liu, H. C., Yeh, T. C., & Chen, S. H. (2021). Comparison of two quantitative PCR–based assays for detection of minimal residual disease in B-precursor acute lymphoblastic leukaemia harbouring three major fusion transcripts. The Journal of Molecular Diagnostics. 23(10), 1373-9 https://doi.org/10.1016/j.jmoldx.2021.07.008
  • Martinez, R. J., Kang, Q., Nennig, D., Bailey, N. G., Brown, N. A., & Betz, B. L. (2022). One- Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. Archives of Pathology & Laboratory Medicine. 146(1), 92-100. https://doi.org/10.5858/arpa.2020-0454-OA
  • Beldinanzi, M., Della, S. I., Cardinali, D., Bellomarino, V., Elia, L., & Matarazzo, M. (2022). Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis . Blood. 140, 11866-7. https://doi.org/10.1182/blood-2022-163141
  • Ansuinelli, M., Della, S. I., Lauretti, A., Elia, L., Siravo, V., & Messina, M. (2021). Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. Hematological Oncology. 39(5), 680-6. https://doi.org/10.1002/hon.2913
  • Guan, Y., Zhang, M., Zhang, W., Wang, J., Shen, K., & Zhang, K. (2021). Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy. Frontiers in Oncology. 11, 646499. https://doi.org/10.3389/fonc.2021.646499
  • Saha, J., Gopinath, V., Nair, C. K., & Roshan, D. (2023). Identification of rare atypical BCR- ABL1 transcript: A case report. https://doi.org/10.4103/ijpm.ijpm_715_21
  • Saygin, C., Cannova, J., Stock, W., & Muffly, L. (2022). Measurable residual disease in acute lymphoblastic leukaemia: methods and clinical context in adult patients. Haematologica. 107(12), 2783-93. https://doi.org/10.3324/haematol.2022.280638
  • Tierens, A., Stockley, T. L., Campbell, C., Fulcher, J., Leber, B., & McCready, E. (2021). Consensus recommendations for MRD testing in adult B-cell acute lymphoblastic leukaemia in Ontario. Current Oncology. 28(2), 1376-87. https://doi.org/10.3390/curroncol28020131
  • Stella, S., Gottardi, E. M., Favout, V., Barragan, G. E., Errichiello, S., & Vitale, S. R. (2019). The q-lamp method represents a valid and rapid alternative for the detection of the bcr-abl1 rearrangement in Philadelphia-positive leukaemias . International Journal of Molecular Sciences. 20(24), 6106. https://doi.org/10.3390/ijms20246106
  • Fukutsuka, K., Kuramura, A., Nakagawa, M., Takahashi, R., Chagi, Y., & Nakagawa, M. (2022). Philadelphia chromosome-positive acute lymphoblastic leukaemia carrying the p230 μ-BCR-ABL1 fusion gene. Tenri Medical Bulletin, 25(1), 29-40. https://doi.org/10.12936/tenrikiyo.25-006
  • Chong, S. L., Asnawi, A. W. A., Leong, T. S., Tan, J. T., Law, K. B., & Hon, S.L. (2021). Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukaemia. Blood research. 56(3), 175-83. https://doi.org/10.5045/br.2021.2021045
  • Smith, B. M., Brewer, D., Druker, B. J., & Braun, T. P. (2021). Navigating challenges in monitoring chronic myeloid leukaemia with multiple BCR-ABL1 transcripts. Case Reports in Oncology. 14, 1707-11. https://doi.org/10.1159/000520400
  • Piedimonte, M., Ottone, T., Alfonso, V., Ferrari, A., Conte, E., & Divona, M. (2019). A rare BCR-ABL1 transcript in Philadelphia- positive acute myeloid leukaemia: case report and literature review. BMC cancer. 19, 1-6. https://doi.org/10.1186/s12885-019-5265-5
  • Chen, Y., Lu, Q. Y., Lu, J. Y., & Hong, X. L. (2022). Primary isolated central nervous system acute lymphoblastic leukaemia with BCR-ABL1 rearrangement: A case report. World Journal of Clinical Cases. 10(13), 4242. https://doi.org/10.12998/wjcc.v10.i13.4242
  • Pfeifer, H., Cazzaniga, G., Van der Velden, V., Cayuela, J., Schäfer, B., & Spinelli, O. (2019). Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukaemia. 33(8), 1910-22. https://doi.org/10.1038/s41375-019-0413-0
  • Podvin, B., Guermouche, H., Roynard, P., Goursaud, L., Berthon, C., & Ouafi, M. (2022). Subclonal acquisition of a BCR:: ABL1 fusion in chronic myelomonocytic leukaemia. Annals of Hematology, 101(9), 2093-5. https://doi.org/10.1007/s00277-022-04861-4
  • Zuna, J., Hovorkova, L., Krotka, J., Koehrmann, A., Bardini, M., & Winkowska, L. (2022). Minimal residual disease in BCR:: ABL1- positive acute lymphoblastic leukaemia: different significance in typical ALL and in CML-like disease. Leukaemia, 1-9. https://doi.org/10.1038/s41375-022-01668-0
  • Shires, K., & Rust, A. (2020). Novel multiplex RT-PCR assay to detect BCR/ABL mRNA variants. The Journal of Medical Laboratory Science and Technology of South Africa. 2(1), 29-35.
  • Correia, R. P., Bento, L. C., Sousa, F. A., Barroso, R. S., Campregher, P. V., & Bacal, N. S. (2021). How I investigate minimal residual disease in acute lymphoblastic leukaemia. International Journal of Laboratory Hematology. 43(3), 354-63. https://doi.org/10.1111/ijlh.13463
  • Short, N. J., Jabbour, E., Albitar, M., de Lima, M., Gore, L., & Jorgensen, J. (2019). Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukaemia: a consensus of North American experts. American journal of haematology, 94(2), 257- 65. https://doi.org/10.1002/ajh.25338
  • Della Starza, I., De Novi, L. A., Elia, L, Bellomarino, V., Beldinanzi, M., & Soscia, R, (2023). Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers. 15(2), 374. https://doi.org/10.3390/cancers15020374

Cite this article

APA

    APA : Munir, G., Gulrukh., & Tariq, H. (2022). Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia. Global Drug Design & Development Review, VII(IV), 39-47. https://doi.org/10.31703/gdddr.2022(VII-IV).05

CHICAGO

    CHICAGO : Munir, Gulshan, Gulrukh, and Hafsa Tariq. 2022. "Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia." Global Drug Design & Development Review, VII (IV): 39-47 doi: 10.31703/gdddr.2022(VII-IV).05

HARVARD

    HARVARD : MUNIR, G., GULRUKH. & TARIQ, H. 2022. Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia. Global Drug Design & Development Review, VII, 39-47.

MHRA

    MHRA : Munir, Gulshan, Gulrukh, and Hafsa Tariq. 2022. "Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia." Global Drug Design & Development Review, VII: 39-47

MLA

    MLA : Munir, Gulshan, Gulrukh, and Hafsa Tariq. "Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia." Global Drug Design & Development Review, VII.IV (2022): 39-47 Print.

OXFORD

    OXFORD : Munir, Gulshan, Gulrukh, , and Tariq, Hafsa (2022), "Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia", Global Drug Design & Development Review, VII (IV), 39-47

TURABIAN

    TURABIAN : Munir, Gulshan, Gulrukh, and Hafsa Tariq. "Development of Real-Time Quantitative PCR Assay for Detection and Monitoring of BCR ABL1 P190 Transcript in Acute Lymphoblastic Leukemia." Global Drug Design & Development Review VII, no. IV (2022): 39-47. https://doi.org/10.31703/gdddr.2022(VII-IV).05